These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday.The company posted quarterly losses of $2.77 per share which beat the analyst consensus estimate of losses of$4.16 per share. The company reported quarterly sales of $30.02 million which missed the analyst consensus estimate of$35.24 million.“We are pleased that our Phase 3 SENTRY trial in patients with JAKi-naïve myelofibrosis has passed its pre-specified futility analysis and continues as planned without m ...